|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
DE68916959T2
(de)
|
1988-03-02 |
1995-01-19 |
Uab Research Foundation |
Reversibel mechanisch-chemisch arbeitende maschinen, die aus bioelastomeren bestehen, die zu regelbaren inversen temperaturübergängen fähig sind, zur umwandlung von chemischer in mechanische arbeit.
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
ES2236178T3
(es)
|
2000-02-22 |
2005-07-16 |
Banyu Pharmaceutical Co., Ltd. |
Nuevos compuestos de imidazolina.
|
|
US6784291B2
(en)
|
2000-05-04 |
2004-08-31 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
JP2002253259A
(ja)
|
2001-03-02 |
2002-09-10 |
Bio Applied Systems:Kk |
抗ビスフェノールａ抗体をコードする遺伝子、組換えタンパク質およびその製造方法
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US7575886B2
(en)
|
2002-03-11 |
2009-08-18 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
|
JP4777777B2
(ja)
|
2002-11-25 |
2011-09-21 |
雅文 松尾 |
ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
|
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
ATE496893T1
(de)
|
2002-12-20 |
2011-02-15 |
X Ceptor Therapeutics Inc |
Isochinolinonderivate und deren verwendung als medikamente
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
JP2008504222A
(ja)
|
2003-12-15 |
2008-02-14 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
新規の抗ｄｃ−ｓｉｇｎ抗体
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
ATE498685T1
(de)
|
2004-06-28 |
2011-03-15 |
Univ Western Australia |
Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
DK1812031T3
(en)
|
2004-11-01 |
2015-09-14 |
Univ California |
Compositions and methods for the modification of biomolecules
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
US20060252107A1
(en)
|
2005-02-22 |
2006-11-09 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
EP2623986B1
(en)
|
2006-02-10 |
2017-06-14 |
Life Technologies Corporation |
Labeling and detection of post translationally modified proteins
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
PL2121751T3
(pl)
|
2006-12-08 |
2017-07-31 |
Lexicon Pharmaceuticals, Inc. |
Przeciwciała monoklonalne przeciwko ANGPTL3
|
|
ES2650224T3
(es)
*
|
2007-08-21 |
2018-01-17 |
Amgen, Inc. |
Proteínas de unión al antígeno C-FMS humano
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CN112574988A
(zh)
|
2008-10-24 |
2021-03-30 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
JP5786109B2
(ja)
|
2008-10-27 |
2015-09-30 |
プロセンサ テクノロジーズ ベー．フェー． |
Ｄｕｃｈｅｎｎｅ型筋ジストロフィーｍＲＮＡ前駆体のエクソン４５の効率的なスキッピングのための方法及び手段
|
|
CA2759899A1
(en)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
ES2618572T3
(es)
|
2009-05-08 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
LT2499249T
(lt)
|
2009-11-12 |
2018-12-27 |
The University Of Western Australia |
Priešprasmės molekulės ir patologijų gydymo būdai
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
WO2011130164A2
(en)
|
2010-04-13 |
2011-10-20 |
The Regents Of The University Of California |
Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
|
|
DK2528625T3
(da)
*
|
2010-04-15 |
2013-10-14 |
Spirogen Sarl |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
DK2563753T6
(en)
|
2010-04-27 |
2016-04-04 |
Synaffix Bv |
Fused cyclooctynforbindelser and their use in metal-free click-reactions
|
|
KR20200133284A
(ko)
|
2010-05-28 |
2020-11-26 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
WO2012007896A1
(en)
|
2010-07-12 |
2012-01-19 |
Covx Technologies Ireland, Ltd. |
Multifunctional antibody conjugates
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
US20120225034A1
(en)
|
2010-09-02 |
2012-09-06 |
Universite De Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
AR084020A1
(es)
|
2010-11-30 |
2013-04-17 |
Genentech Inc |
Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
|
|
PE20141114A1
(es)
|
2010-12-20 |
2014-09-15 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados
|
|
EP2672977A1
(en)
|
2011-02-08 |
2013-12-18 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Antisense oligonucleotides
|
|
CA2828890A1
(en)
*
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
JP2014523884A
(ja)
|
2011-06-24 |
2014-09-18 |
セントローズ， エルエルシー |
細胞外標的化薬物複合体
|
|
RU2014109038A
(ru)
|
2011-08-23 |
2015-09-27 |
Рош Гликарт Аг |
Антитела к хондроитинсульфат протеогликану меланомы
|
|
WO2013036748A1
(en)
|
2011-09-09 |
2013-03-14 |
Berry, Lana, L. |
Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
|
|
CA2858347C
(en)
|
2011-12-05 |
2020-07-07 |
New York University |
V1v2 immunogens
|
|
US9725716B2
(en)
|
2011-12-06 |
2017-08-08 |
Ohio State Innovation Foundation and Research Institute at Nationwide Children's Hospital |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
CN117721110A
(zh)
|
2011-12-28 |
2024-03-19 |
日本新药株式会社 |
反义核酸
|
|
TW201333040A
(zh)
|
2012-01-06 |
2013-08-16 |
Bioalliance Cv |
抗－輸鐵蛋白受器之抗體及其使用方法
|
|
TW201341401A
(zh)
|
2012-01-09 |
2013-10-16 |
Covx Technologies Ireland Ltd |
突變抗體及其共軛
|
|
PE20190658A1
(es)
|
2012-02-24 |
2019-05-08 |
Abbvie Stemcentrx Llc |
Moduladores y metodos de empleo novedosos
|
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
|
SMT201700339T1
(it)
|
2012-04-23 |
2017-09-07 |
Biomarin Tech Bv |
Oligonucleotidi di modulazione dell'rna con caratteristiche migliorate per il trattamento dei disturbi neuromuscolari
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
FI2911699T4
(fi)
|
2012-10-23 |
2025-12-09 |
Synaffix Bv |
Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
BR112015019909A2
(pt)
|
2013-02-22 |
2017-08-29 |
Abbvie Stemcentrx Llc |
Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
|
|
NZ731587A
(en)
|
2013-03-14 |
2021-07-30 |
Sarepta Therapeutics Inc |
Exon skipping compositions for treating muscular dystrophy
|
|
RS58529B1
(sr)
|
2013-03-14 |
2019-04-30 |
Sarepta Therapeutics Inc |
Sastavi koji preskaču egzon za tretiranje mišićne distrofije
|
|
CA2906812A1
(en)
|
2013-03-15 |
2014-09-18 |
Sarepta Therapeutics, Inc. |
Improved compositions for treating muscular dystrophy
|
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
EP3004370B1
(en)
|
2013-06-05 |
2024-08-21 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
PE20160209A1
(es)
|
2013-08-28 |
2016-05-09 |
Stemcentrx Inc |
Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso
|
|
WO2015042581A1
(en)
|
2013-09-23 |
2015-03-26 |
President And Fellows Of Harvard College |
Allele-specific rna silencing for the treatment of hypertrophic cardiomyopathy
|
|
EP3058083B1
(en)
|
2013-10-14 |
2018-04-11 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
EP3057618B1
(en)
|
2013-10-14 |
2022-12-14 |
SynAffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
US10344284B2
(en)
|
2013-11-14 |
2019-07-09 |
Lina A. Shehadeh |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
CN106660967A
(zh)
|
2014-01-24 |
2017-05-10 |
西纳福克斯股份有限公司 |
(杂)芳基1，3‑偶极化合物与(杂)环炔的环加成方法
|
|
WO2015112016A1
(en)
|
2014-01-24 |
2015-07-30 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
JP2017513921A
(ja)
|
2014-03-03 |
2017-06-01 |
アーチャルジー、スジャータ |
ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
|
|
SMT201900169T1
(it)
|
2014-03-12 |
2019-05-10 |
Nippon Shinyaku Co Ltd |
Acido nucleico antisenso
|
|
AR099625A1
(es)
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
US20170182189A1
(en)
|
2014-05-23 |
2017-06-29 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
RU2695430C2
(ru)
|
2014-06-17 |
2019-07-23 |
Ниппон Синяку Ко., Лтд. |
Антисмысловые нуклеиновые кислоты
|
|
EP3177633B1
(en)
|
2014-08-04 |
2022-07-20 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
WO2016053107A1
(en)
|
2014-10-03 |
2016-04-07 |
Synaffix B.V. |
Sulfamide linker, conjugates thereof, and methods of preparation
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
EA036714B1
(ru)
|
2014-11-21 |
2020-12-10 |
Мерк Шарп И Доум Корп. |
Частичные агонисты инсулинового рецептора
|
|
CN107810273B
(zh)
|
2015-04-23 |
2022-09-27 |
西纳福克斯股份有限公司 |
用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
EP3297649B1
(en)
|
2015-05-19 |
2023-10-11 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
WO2016205641A2
(en)
|
2015-06-17 |
2016-12-22 |
Research Institute At Nationwide Children's Hospital |
Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods
|
|
PT3325509T
(pt)
|
2015-07-22 |
2021-03-12 |
Inatherys |
Anticorpos anti-tfr e sua utilização no tratamento de distúrbios proliferativos e inflamatórios
|
|
SI3351633T1
(sl)
|
2015-09-15 |
2020-09-30 |
Nippon Shinyaku Co., Ltd. |
Protismiselna nukleinska kislina
|
|
US20180265859A1
(en)
|
2015-09-23 |
2018-09-20 |
UNIVERSITé LAVAL |
Modification of the dystrophin gene and uses thereof
|
|
EP3858993A1
(en)
*
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
JP7511326B2
(ja)
|
2015-10-09 |
2024-07-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物およびその方法
|
|
AU2016365834B2
(en)
|
2015-12-08 |
2023-09-28 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
US11135304B2
(en)
|
2015-12-18 |
2021-10-05 |
Eisai R&D Management Co., Ltd. |
C-terminal lysine conjugated immunoglobulins
|
|
WO2017137423A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Improved sulfamide linkers for use in bioconjugates
|
|
IL260983B
(en)
|
2016-02-19 |
2022-07-01 |
Genisphere Llc |
Nucleic acid carriers and methods of medical use
|
|
HRP20230528T1
(hr)
|
2016-03-22 |
2023-08-04 |
F. Hoffmann - La Roche Ag |
Bispecifične molekule t stanica aktivirane proteazom
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
WO2017192679A1
(en)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd. |
Methods and compositions of biologically active agents
|
|
EP3463429A4
(en)
|
2016-05-24 |
2020-07-22 |
Merck Sharp & Dohme Corp. |
PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES
|
|
TWI737736B
(zh)
|
2016-05-24 |
2021-09-01 |
美商薩羅塔治療公司 |
製備磷醯二胺嗎啉代寡聚物之方法
|
|
CN109562122A
(zh)
|
2016-06-03 |
2019-04-02 |
波涛生命科学有限公司 |
寡核苷酸、组合物及其方法
|
|
CN109310765A
(zh)
|
2016-06-20 |
2019-02-05 |
领先基因生物技术股份有限公司 |
抗体-药物偶联物
|
|
CA3029772A1
(en)
|
2016-07-05 |
2018-01-11 |
Biomarin Technologies B.V. |
Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
|
|
US20190330626A1
(en)
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
IL266690B2
(en)
|
2016-11-16 |
2024-06-01 |
Biomarin Tech Bv |
Substances for targeting various selected organs or tissues
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
CA3044531A1
(en)
|
2016-11-28 |
2018-05-31 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
|
|
JP2020500541A
(ja)
|
2016-12-08 |
2020-01-16 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
ヒト化デュシェンヌ型筋ジストロフィー変異を有するｄｍｄレポーターモデル
|
|
TWI761413B
(zh)
|
2016-12-26 |
2022-04-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
WO2018140831A2
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
FI3635009T3
(fi)
|
2017-06-07 |
2026-04-07 |
Regeneron Pharma |
Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
|
|
JP7073487B2
(ja)
|
2017-06-16 |
2022-05-23 |
イーライ リリー アンド カンパニー |
操作された抗体化合物およびこれらの抱合体
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
US20200282074A1
(en)
|
2017-09-22 |
2020-09-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
WO2019067975A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
WO2019071028A1
(en)
|
2017-10-04 |
2019-04-11 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
|
US20210363521A1
(en)
|
2017-11-09 |
2021-11-25 |
Vertex Pharmaceuticals Incorporated |
CRISPR/CAS Systems For Treatment of DMD
|
|
JP7506601B2
(ja)
|
2017-12-06 |
2024-06-26 |
アビディティー バイオサイエンシーズ，インク． |
筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
|
|
CN108220418B
(zh)
|
2017-12-29 |
2018-11-09 |
东莞博奥木华基因科技有限公司 |
基于多重pcr捕获技术的杜氏/贝氏肌营养不良症的检测试剂盒及方法
|
|
MA51583A
(fr)
|
2018-01-04 |
2020-11-11 |
Avidity Biosciences Inc |
Molécules d'acide nucléique hétéroduplex et leurs utilisations
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
JP2021511803A
(ja)
|
2018-01-31 |
2021-05-13 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
ヒト心筋細胞におけるジストロフィン変異を修正するための組成物および方法
|
|
AU2019215782A1
(en)
|
2018-02-05 |
2020-07-16 |
Jcr Pharmaceuticals Co., Ltd. |
Method for delivering drug to muscle
|
|
JP7779653B2
(ja)
|
2018-02-07 |
2025-12-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療用タンパク質送達のための方法および組成物
|
|
IL277889B2
(en)
|
2018-04-12 |
2025-01-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods of using them
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
CA3098266A1
(en)
|
2018-05-11 |
2019-11-14 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019241385A2
(en)
|
2018-06-13 |
2019-12-19 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystropy
|
|
US20210261962A1
(en)
|
2018-06-21 |
2021-08-26 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP2021533197A
(ja)
|
2018-08-02 |
2021-12-02 |
ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. |
ポンペ病を処置するための筋標的化複合体およびそれらの使用
|
|
JP7576542B2
(ja)
|
2018-08-02 |
2024-10-31 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびそれらの使用
|
|
WO2020028842A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP3829595A4
(en)
|
2018-08-02 |
2022-08-24 |
Dyne Therapeutics, Inc. |
MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
|
|
US20220193250A1
(en)
|
2018-08-02 |
2022-06-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
EP3830130A4
(en)
|
2018-08-02 |
2022-05-18 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
CA3108328A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
|
|
CN112930193A
(zh)
|
2018-08-02 |
2021-06-08 |
达因疗法公司 |
肌肉靶向复合物及其在治疗肌肉萎缩中的用途
|
|
KR20210086601A
(ko)
|
2018-08-02 |
2021-07-08 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
|
|
IL321905A
(en)
|
2018-08-02 |
2025-09-01 |
Dyne Therapeutics Inc |
Muscle-targeted conjugates and their uses in the treatment of myotonia dystrophica
|
|
CN109306375A
(zh)
|
2018-10-16 |
2019-02-05 |
上海瀚垚生物医学科技有限公司 |
EvaGreen法数字PCR检测DMD拷贝数变异的引物、检测试剂盒及其检测方法
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
CN113260384A
(zh)
|
2018-11-05 |
2021-08-13 |
西纳福克斯股份有限公司 |
用于靶向表达trop-2的肿瘤的抗体缀合物
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
US12497615B2
(en)
*
|
2019-04-25 |
2025-12-16 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
KR20220019259A
(ko)
|
2019-06-06 |
2022-02-16 |
어비디티 바이오사이언시스 인크. |
Una 아미다이트 및 이의 용도
|
|
JP7592034B2
(ja)
|
2019-06-06 |
2024-11-29 |
アビディティー バイオサイエンシーズ，インク． |
核酸ポリペプチド組成物およびその使用
|
|
CN119874910A
(zh)
|
2019-06-07 |
2025-04-25 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
US20220288218A1
(en)
|
2019-07-09 |
2022-09-15 |
The Governors Of The University Of Alberta |
Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
|
|
US12479922B2
(en)
|
2019-10-10 |
2025-11-25 |
Cytolynx Therapeutics Hong Kong Limited |
Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2021142313A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
KR20220125801A
(ko)
|
2020-01-10 |
2022-09-14 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
JP7780691B2
(ja)
|
2020-01-10 |
2025-12-05 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
CA3163283A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2023283531A2
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
AU2021206234A1
(en)
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2021150382A1
(en)
|
2020-01-24 |
2021-07-29 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
CN115427059A
(zh)
|
2020-01-31 |
2022-12-02 |
达因疗法公司 |
抗转铁蛋白受体（tfr）抗体及其用途
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
KR20230044242A
(ko)
*
|
2020-07-23 |
2023-04-03 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
CN116348138A
(zh)
|
2020-07-23 |
2023-06-27 |
达因疗法公司 |
抗转铁蛋白受体（tfr）抗体及其用途
|
|
KR20230046297A
(ko)
|
2020-07-23 |
2023-04-05 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
AU2021318851A1
(en)
|
2020-07-23 |
2023-03-16 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2022020108A1
(en)
|
2020-07-23 |
2022-01-27 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
US20230346966A1
(en)
|
2020-07-23 |
2023-11-02 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
WO2022051665A1
(en)
|
2020-09-03 |
2022-03-10 |
Dyne Therapeutics, Inc. |
Methods of preparing protein-oligonucleotide complexes
|
|
IL301187A
(en)
|
2020-09-11 |
2023-05-01 |
Arrowhead Pharmaceuticals Inc |
RNAi agents for suppressing DUX4 expression, preparations containing them and uses thereof
|
|
US20240100177A1
(en)
|
2020-12-04 |
2024-03-28 |
Dyne Therapeutics, Inc. |
Antibody-oligonucleotide complexes and uses thereof
|
|
JP2024501872A
(ja)
|
2020-12-31 |
2024-01-16 |
ダイン セラピューティクス，インコーポレーテッド |
顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
|
US20240117356A1
(en)
|
2020-12-31 |
2024-04-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP4359534A1
(en)
|
2021-06-21 |
2024-05-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CN118251238A
(zh)
|
2021-06-21 |
2024-06-25 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途
|
|
IL309912A
(en)
|
2021-07-09 |
2024-03-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and their uses for the treatment of dystrophinopathy
|
|
KR20240032945A
(ko)
|
2021-07-09 |
2024-03-12 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
MX2024000490A
(es)
|
2021-07-09 |
2024-04-10 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de los mismos para tratar las distrofinopatías.
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP4366783A4
(en)
|
2021-07-09 |
2025-08-27 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES
|
|
AU2022306307A1
(en)
|
2021-07-09 |
2024-02-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
IL309936A
(en)
|
2021-07-09 |
2024-03-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of dystrophinopathy
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CA3226300A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
IL311507A
(en)
|
2021-09-16 |
2024-05-01 |
Dyne Therapeutics Inc |
Dosing of muscle targeting complexes for the treatment of dystrophinopathy
|
|
JP2024540199A
(ja)
|
2021-11-01 |
2024-10-31 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィノパチーを処置するための筋標的化複合体
|
|
KR20240099448A
(ko)
|
2021-11-12 |
2024-06-28 |
다인 세라퓨틱스, 인크. |
안면견갑상완 근육 이영양증을 치료하기 위한 근육 표적화 복합체
|
|
KR20250004771A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여
|
|
WO2023201318A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
EP4508091A1
(en)
|
2022-04-15 |
2025-02-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20250339553A1
(en)
|
2022-04-15 |
2025-11-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
KR20250034419A
(ko)
|
2022-07-06 |
2025-03-11 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
MA71403A
(fr)
|
2022-07-06 |
2025-04-30 |
Dyne Therapeutics, Inc. |
Complexes de ciblage du snc et leurs utilisations
|
|
JP2026503873A
(ja)
|
2022-10-31 |
2026-02-02 |
ダイン セラピューティクス，インコーポレーテッド |
Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用
|